To study on 65 HBsAg positive mothers and 61 their newborns received differents dosages and types of hepatitis B vaccine at 0, 1, 2 months. HBeAg was detected in 25 (38.5%) mothers and all of them were HBV DNA positive. HBsAg and HBV DNA was detected in 19 (76%) and 23 (92%) respectively of the 25 cord blood from HBeAg positive mothers, while detected in 16 (40%) and 12 (30%) respectively of the 40 cord blood from HBeAg negative mothers. Testing at 6 months after completion of the vaccineation schedule, the failure risk (HBsAg positive) of vaccines for dosage of 2.5 g/ml is higher than others (5 g/ml and 10 g/ml). Hepatitis B vaccine with hepatitis B immune globulin or vaccine dosages of 5 and 10g alone may be recommended for high-risk neonates.
Hepatectomy ; Hepatic Veins ; Surgery, Plastic ; Liver Transplantation

2 reduced doses of plasma-derived hepatitis B vaccine produced by the National Institute of Hygiene an Epidemiology (NIHE): 2.5g (VN2,5) and 5g (VN5) was compared with 2 pediatric standard doses (10g) of recombinant vaccine from 2 Korean companies. The vaccines were administrated intramuscularly in 700 neonates at months 0, 1, 2 with postvaccineation serology tested at month 8. The seroconversion rate of 2 reduced doses are comparable with 2 control groups. Geometric mean titer of low-risk newborns in group VN2,5 were similar to group VN5, but significantly lower than control groups.
Hepatitis B ; Infant, Newborn ; Hepatitis B Vaccines

A serum panel from Vietnamese blood donors including 225 positive and 300 negative sera has been used to evaluate antigenicity of 8 hepatitis C virus (HCV) recombinant proteins cloned and expressed in Escherichia coli c22-3, c33/1b, mosaic NS4, NS5a/1b proteins presented identical results while third-generation HCV recombinant immunoblot assay (RIBA-3) sera were positive. All recombinant proteins highly detected HCV RNA positive sera known genotype (80-95%). NS3-16/6a demonstrated greater reactivity than other proteins, indeed a good protein (c33c/1b) in the same region while HCV genotype was 6a (specific HCV genotype in Vietnam).
Hepatitis C virus ; Escherichia coli

4 hepatitis C virus (HCV) recombinant proteins with GST (glutathione S-transferase) structure expressed in Escherichia coli was purified for developing a third-generation anti-HCV Enzyme Immunoassay - GST anti-HCV EIA-3. This diagnostic kit was able to detect all HCV RIBA-3 positive sera or HCV RIBA-3 indeterminate (only one reactive band) and PCR positive sera in HCV panels from Russian and Indonesian blood donors, US HCV genotype panel. With HCV RIBA-3 indeterminate specimens, this test is strongly reactive (at least 2 antigens) while core or NS3 band are positive and non-reactive while NS4 or NS5 band are positive.
Hepatitis C ; Escherichia coli

Objective: The purpose of this survey was to estimate the prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Viet Nam using a nationally representative sampling method. Methods: The survey was conducted between May and August 2014 using a two-stage cluster design. Sixteen ART clinics were selected using probability proportional to proxy size sampling, and patients receiving ART for at least 36 months were consecutively enrolled. Epidemiological information and blood specimens were collected for HIV-1 VL and HIVDR testing; HIVDR was defined by the Stanford University HIVDR algorithm. Results: Overall, 365 eligible individuals were recruited with a mean age of 38.2 years; 68.4% were men. The mean time on ART was 75.5 months (95% confidence interval [CI]: 69.0–81.9 months), and 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor-based regimens. Of the 365 individuals, 345 (94.7%, 95% CI: 64.1–99.4%) had VL below 1000 copies/mL and 19 (4.6%, 95% CI: 2.8-–7.5) had HIVDR mutations. Discussion Our nationally representative survey found a high level of VL suppression and a low prevalence of HIVDR among individuals who received ART for at least 36 months in Viet Nam. Continued surveillance for HIVDR is important for evaluating and improving HIV programs.